Michael G. Kauffman
2013
In 2013, Michael G. Kauffman earned a total compensation of $7.3M as Chief Executive Officer at Karyopharm Therapeutics, a 1,483% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $170,000 |
|---|---|
| Option Awards | $6,771,948 |
| Salary | $380,507 |
| Other | $10,258 |
| Total | $7,332,713 |
Kauffman received $6.8M in option awards, accounting for 92% of the total pay in 2013.
Kauffman also received $170K in non-equity incentive plan, $380.5K in salary and $10.3K in other compensation.
Rankings
In 2013, Michael G. Kauffman's compensation ranked 739th out of 12,286 executives tracked by ExecPay. In other words, Kauffman earned more than 94.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 739 out of 12,286 | 94th |
Division Manufacturing | 240 out of 4,612 | 95th |
Major group Chemicals And Allied Products | 65 out of 1,466 | 96th |
Industry group Drugs | 40 out of 1,160 | 97th |
Industry Pharmaceutical Preparations | 36 out of 890 | 96th |
Source: SEC filing on April 7, 2015.
Kauffman's colleagues
We found two more compensation records of executives who worked with Michael G. Kauffman at Karyopharm Therapeutics in 2013.
News
Karyopharm Therapeutics CEO Richard Paulson receives $8.4M in 2021
April 8, 2022
Karyopharm Therapeutics CEO Michael Kauffman's 2020 pay jumps 22% to $3.9M
April 7, 2021
Karyopharm Therapeutics CEO Michael Kauffman's 2019 pay jumps 42% to $3.2M
April 9, 2020
Karyopharm Therapeutics Executive Vice President, Chief Commercial Officer Anand Varadan receives $2.3M in 2018
April 19, 2019